Fatigue Severity Scale score
Biomarker1 paper1 finding
- Human trial1
Interventions
1Fluvoxamine
downin humans1High certainty
1 study
Fluvoxamine
downin humans1High certainty
Fluvoxamine decreases Fatigue Severity Scale score in humans (Mean difference versus placebo: -0.43 at day 60 and -0.58 at day 90; 99% posterior probability of superiority at both times).
Human triallong COVID-associated fatigue; compared with placebo100 mg twice daily60 days of treatment; assessment at day 90
Fluvoxamine may ease fatigue in adults with long COVID · Annals of internal medicine · 6 Oct 2026
Latest
1Annals of Internal MedicineHuman trial
Fluvoxamine may ease fatigue in adults with long COVID
Mean Fatigue Severity Scale scores were 0.43 points lower than placebo at day 60 and 0.58 points lower at day 90.Mean Fatigue Severity Scale scores were 0.43 points lower than placebo at day 60 and 0.58 points lower at day 90.